General Information |
| Summary |
This is a phase 1 study of FT522 administered with rituximab in participants with relapsed/refractory B-cell lymphoma (R/R BCL). The primary objectives of the study are to evaluate the safety and tolerability of FT522 in combination with rituximab, and to determine the recommended phase 2 dose (RP2D) of FT522 in combination with rituximab; each objective will be assessed with or without conditioning chemotherapy. |
| Clinical trials phase |
Phase 1 |
| Start date (estimated) |
2023-09-01 |
| End date (estimated) |
2039-12-31 |
| Clinical feature |
| Label |
B-cell lymphoma |
| Link |
http://purl.obolibrary.org/obo/DOID_707 |
| Description |
A non-Hodgkin lymphoma that has_material_basis_in B cells. |
|
Administrative Information |
| NCT number |
NCT05950334 |
| ICTRP weblink |
https://trialsearch.who.int/Trial2.aspx?TrialID=NCT05950334 |
| Other study identifiers |
|
| Source weblink |
https:/clinicaltrials.gov/ct2/show/NCT05950334 |
| Regulatory body approval |
| Name |
Food and Drug Administration (FDA) |
| Country |
|
|
| Public contact |
| Email |
info@fatetherapeutics.com |
| Public email |
info@fatetherapeutics.com |
|
| Sponsors |
Fate Therapeutics
|
Cells |
| Which differentiated cell type is used |
| Label |
natural killer cell |
| Link |
http://purl.obolibrary.org/obo/CL_0000623 |
| Description |
A lymphocyte that can spontaneously kill a variety of target cells without prior antigenic activation via germline encoded activation receptors and also regulate immune responses via cytokine release and direct contact with other cells. |
|
Recruitment |
| Recruitment Status |
Not yet recruiting |
| Estimated number of participants |
322 |
